Dianthus Therapeutics (DNTH) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed UroGen Pharma (URGN) over the past year, gaining 144.6% versus a gain of 141.7%. Over five years, URGN leads with a +139.1% price change compared with -21.2% for DNTH. Dianthus Therapeutics is the larger company by market cap ($4.75 billion vs $1.99 billion), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | URGN |
|---|---|---|
| Share price | $84.88 | $40.70 |
| Market cap | $4.75B | $1.99B |
| 1-day change | -0.61% | -1.76% |
| YTD return | +105.97% | +73.78% |
| 1-year return | +144.61% | +141.69% |
| 5-year return | -21.17% | +139.13% |
| Forward P/E | — | 14.57 |
| EPS (TTM) | $-4.24 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Revenue growth (YoY) | -67.35% | — |
| Net income (latest FY) | $-162.34M | — |
| Operating margin | -8739.34% | — |
| Net margin | -7973.33% | — |
| 52-week high | $117.88 | $50.81 |
| 52-week low | $32.22 | $15.86 |
| Distance from 52-week high | -27.99% | -19.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +65.88% | +47.42% |
| Average volume | 821.22K | 827.16K |
| Shares outstanding | 55.93M | 48.88M |
| Employees | 92 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Dianthus Therapeutics is about 2.4 times larger than UroGen Pharma by market value ($4.75B vs $1.99B).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
DNTH vs URGN FAQ
Which is bigger, Dianthus Therapeutics or UroGen Pharma?
Dianthus Therapeutics (DNTH) is larger, with a market capitalization of $4.75B compared with $1.99B for UroGen Pharma (URGN).
Which stock has performed better over the past year, DNTH or URGN?
DNTH returned +144.61% over the past 12 months, compared with +141.69% for URGN (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.